Ultra-widefield imaging reveals early retinal risk in pediatric patients.
News|Articles|March 16, 2026
Idiopathic intracranial hypertension: An old disease getting new attention
Author(s)Lynda Charters
Fact checked by: Marc Bouffard, MD, Rudrani Banik, MD
About 90% of patients are female with obesity and potential hormonal drivers
Advertisement
Advertisement
Idiopathic intracranial hypertension (IIH)1,2 has come under increased clinical scrutiny in the last 2 decades. This neurologic disorder is characterized by increased intracranial pressure of unknown origin, and while it was once considered rare, the opposite now may indeed be true, based on the increasing numbers of IIH cases being diagnosed.
Related to this article
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.
Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.
The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.
Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.
A balanced mix of AI-generated and smartphone-captured images eliminated the domain-specific failures seen with single-source training
Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for Stargardt disease type 1.
Advertisement
Advertisement